Published in Blood on January 11, 2013
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat Med (2016) 1.02
Cell-intrinsic in vivo requirement for the E47-p21 pathway in long-term hematopoietic stem cells. J Immunol (2013) 0.83
Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells. J Immunol (2014) 0.80
Human megakaryocyte progenitors derived from hematopoietic stem cells of normal individuals are MHC class II-expressing professional APC that enhance Th17 and Th1/Th17 responses. Immunol Lett (2014) 0.77
IFN-γ-STAT1-iNOS Induces Myeloid Progenitors to Acquire Immunosuppressive Activity. Front Immunol (2017) 0.75
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature (2003) 14.35
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature (2003) 12.06
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell (2008) 11.53
Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science (2000) 10.81
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature (2006) 7.35
Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet (2008) 7.30
IFNalpha activates dormant haematopoietic stem cells in vivo. Nature (2009) 7.17
New functional activities for the p21 family of CDK inhibitors. Genes Dev (1997) 6.97
Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity (2006) 5.98
In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci U S A (1999) 5.65
Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity (2006) 5.47
Stem cell niche: structure and function. Annu Rev Cell Dev Biol (2005) 5.33
Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell (2007) 5.17
Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature (2004) 4.68
Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature (2010) 3.93
Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci U S A (2010) 3.41
Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med (2005) 3.21
Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med (2008) 2.97
Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood (1997) 2.84
Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci U S A (2000) 2.82
Loss of stem cell repopulating ability upon transplantation. Effects of donor age, cell number, and transplantation procedure. J Exp Med (1982) 2.77
HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol (2012) 2.75
In vivo self-renewing divisions of haematopoietic stem cells are increased in the absence of the early G1-phase inhibitor, p18INK4C. Nat Cell Biol (2004) 2.65
p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell (2011) 2.58
p57 is required for quiescence and maintenance of adult hematopoietic stem cells. Cell Stem Cell (2011) 2.54
Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat Rev Immunol (2011) 2.38
Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature (2008) 2.13
Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. J Exp Med (2011) 1.95
Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood (2012) 1.95
A Limited role for p21Cip1/Waf1 in maintaining normal hematopoietic stem cell functioning. Stem Cells (2006) 1.84
Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol (2011) 1.76
Cutting edge: bacterial infection induces hematopoietic stem and progenitor cell expansion in the absence of TLR signaling. J Immunol (2010) 1.56
Dysfunctional expansion of hematopoietic stem cells and block of myeloid differentiation in lethal sepsis. Blood (2009) 1.48
Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.39
Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice. J Clin Invest (2010) 1.34
The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther (2008) 1.33
The effect of bleeding on hematopoietic stem cell cycling and self-renewal. Stem Cells Dev (2007) 1.33
Type I interferon and lupus. Curr Opin Rheumatol (2009) 1.32
Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J Exp Med (2011) 1.27
Haematological manifestations of systemic lupus erythematosus. Blood Rev (1993) 1.25
Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.25
The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate. Leukemia (2009) 1.23
Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood (2003) 1.22
IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest (2006) 1.21
Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther (2012) 1.17
Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals. Blood (2009) 1.17
HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development. Autoimmun Rev (2010) 1.12
Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol (1997) 1.03
Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1. J Immunol (2011) 0.97
A novel function of interleukin-10 promoting self-renewal of hematopoietic stem cells. Stem Cells (2007) 0.96
Apoptosis: the link between autoantibodies and leuko-/lymphocytopenia in patients with lupus erythematosus. Scand J Rheumatol (2004) 0.87
Bacterial infection of human hematopoietic stem cells induces monocytic differentiation. FEMS Immunol Med Microbiol (2004) 0.80
Cellular therapy of systemic lupus erythematosus. Lupus (2009) 0.78
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature (2002) 12.09
Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature (2002) 7.28
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med (2005) 5.50
HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 4.53
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A (2002) 3.68
Cognition and immunity; antibody impairs memory. Immunity (2004) 3.40
Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med (2006) 3.26
Novel role of PKR in inflammasome activation and HMGB1 release. Nature (2012) 3.13
The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.05
Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A (2006) 2.97
HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology (2002) 2.95
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 2.89
Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med (2002) 2.83
Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity (2004) 2.82
Induction of pluripotency in mouse somatic cells with lineage specifiers. Cell (2013) 2.69
Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A (2006) 2.51
Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol (2003) 2.50
High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol (2006) 2.44
CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med (2008) 2.41
Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med (2007) 2.41
On the track of neuropsychiatric lupus. Arthritis Rheum (2003) 2.39
The chemokine SDF1 regulates migration of dentate granule cells. Development (2002) 2.34
Network of dynamic interactions between histone H1 and high-mobility-group proteins in chromatin. Mol Cell Biol (2004) 2.33
High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol (2004) 2.32
Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med (2003) 2.30
Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med (2006) 2.27
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26
IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol (2003) 2.24
Recombinant HMGB1 with cytokine-stimulating activity. J Immunol Methods (2004) 2.14
The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med (2004) 2.14
HMGB1 as a DNA-binding cytokine. J Leukoc Biol (2002) 2.07
Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest (2006) 2.05
Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol (2007) 2.02
Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum (2008) 2.00
Female mouse fetal loss mediated by maternal autoantibody. J Exp Med (2012) 1.92
Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum (2006) 1.87
Murine models of systemic lupus erythematosus. J Biomed Biotechnol (2011) 1.84
IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J Immunol (2007) 1.82
Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med (2006) 1.81
Role of B-1a cells in autoimmunity. Autoimmun Rev (2005) 1.77
Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest (2002) 1.76
The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med (2009) 1.73
XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J Exp Med (2009) 1.71
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proc Natl Acad Sci U S A (2011) 1.66
Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci U S A (2010) 1.65
A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol (2007) 1.60
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med (2008) 1.54
Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol (2004) 1.53
Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med (2009) 1.52
Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int (2007) 1.50
Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol (2004) 1.49
Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis. Crit Care Med (2010) 1.47
B cell selection and susceptibility to autoimmunity. J Immunol (2005) 1.46
Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One (2008) 1.45
Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res (2005) 1.43
Pillars Article: Polygenic Control of Susceptibility to Murine Systemic Lupus Erythematosus. Immunity. 1994. 1: 219-229. J Immunol (2015) 1.42
The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One (2010) 1.42
Chronic sepsis mortality characterized by an individualized inflammatory response. J Immunol (2007) 1.42
Aberrant signaling in the TNFalpha/TNF receptor 1 pathway of the NZM2410 lupus-prone mouse. Clin Immunol (2004) 1.41
Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem (2011) 1.41
The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J Nutr (2006) 1.38
Identification of an antigen-specific B cell population. J Immunol Methods (2003) 1.36
Peripheral nerve-derived CXCL12 and VEGF-A regulate the patterning of arterial vessel branching in developing limb skin. Dev Cell (2013) 1.35
HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med (2012) 1.33
BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum (2005) 1.33
JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A (2014) 1.31
A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One (2007) 1.30
NADPH oxidase deficiency regulates Th lineage commitment and modulates autoimmunity. J Immunol (2010) 1.29
Simultaneous determination of six active components in crude and processed Fructus Corni by high performance liquid chromatography. J Pharm Biomed Anal (2008) 1.28
Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by differentiation into renal tubular epithelial-like cells. Int J Mol Med (2008) 1.28
Tolerogenic function of Blimp-1 in dendritic cells. J Exp Med (2011) 1.26
Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis. Mol Med (2012) 1.26
A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One (2011) 1.25
ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur J Immunol (2007) 1.25
Alpha-chemokine receptor blockade reduces high mobility group box 1 protein-induced lung inflammation and injury and improves survival in sepsis. Am J Physiol Lung Cell Mol Physiol (2005) 1.24
Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum (2012) 1.23
IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest (2006) 1.21
Association between alcohol consumption and cancers in the Chinese population--a systematic review and meta-analysis. PLoS One (2011) 1.20
HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine (2002) 1.19
Peroxisome proliferator-activated receptor {delta} is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart. Circ Res (2010) 1.19
Genetic determination of T cell help in loss of tolerance to nuclear antigens. J Immunol (2005) 1.18
HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4. Am J Physiol Lung Cell Mol Physiol (2013) 1.17
Requirement for cyclin D3 in germinal center formation and function. Cell Res (2010) 1.16
CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat Genet (2012) 1.16
A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci U S A (2003) 1.16
Arabidopsis cryptochrome 2 (CRY2) functions by the photoactivation mechanism distinct from the tryptophan (trp) triad-dependent photoreduction. Proc Natl Acad Sci U S A (2011) 1.15
Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J Autoimmun (2009) 1.15
Prolactin modulates the naive B cell repertoire. J Clin Invest (2003) 1.14
Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol (2011) 1.13
HMGB1 is a bone-active cytokine. J Cell Physiol (2008) 1.13
Hormonal modulation of B cell development and repertoire selection. Mol Immunol (2005) 1.12
The major murine systemic lupus erythematosus susceptibility locus Sle1 results in abnormal functions of both B and T cells. J Immunol (2002) 1.10
Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis Rheum (2010) 1.10
Neurocognitive impairment in childhood-onset systemic lupus erythematosus: measurement issues in diagnosis. Arthritis Care Res (Hoboken) (2011) 1.08
Receptor editing in peripheral B cell tolerance. Proc Natl Acad Sci U S A (2005) 1.08